ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07875
-0,01%
Bitcoin
60.909,44
0,19%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) News

NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NKTR
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
09/05/202422h15PR Newswire (US)Nektar Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
03/05/202400h00PR Newswire (US)Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
22/03/202419h00PR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
05/03/202423h11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NKTRNektar Therapeutics
05/03/202415h00PR Newswire (US)Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataNASDAQ:NKTRNektar Therapeutics
04/03/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
04/03/202422h15PR Newswire (US)Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
04/03/202414h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
04/03/202414h30PR Newswire (US)Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNASDAQ:NKTRNektar Therapeutics
28/02/202400h00PR Newswire (US)Nektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:NKTRNektar Therapeutics
27/02/202400h00PR Newswire (US)Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
23/02/202402h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
23/02/202402h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
23/02/202402h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
20/02/202421h55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
20/02/202421h51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
20/02/202421h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
16/02/202423h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
14/02/202423h03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
14/02/202414h50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
10/01/202422h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
04/01/202400h00PR Newswire (US)Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CANASDAQ:NKTRNektar Therapeutics
16/12/202300h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
16/12/202300h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
16/12/202300h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
15/12/202318h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
12/12/202300h00PR Newswire (US)Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:NKTRNektar Therapeutics
27/11/202322h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
21/11/202303h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
 Showing the most relevant articles for your search:NASDAQ:NKTR

Kürzlich von Ihnen besucht

FX
EURUSD
Euro vs US Dollar
NYSE
DIS
Walt Disney
NASDAQ
NVDA
NVIDIA
AMEX
XLV
Health Care Select Sector
FX
EURGBP
Euro vs Sterling
CCOM
US100
US Tech 100
TG
LHA
Deutsche Lufthansa
TG
DTE
Deutsche Telekom
CCOM
US30
US 30
COIN
ETHUSD
Ethereum
FX
EURJPY
Euro vs Yen
CCOM
US500
US 500
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
TG
ALV
Allianz
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten